Crinetics Pharmaceuticals Receives Positive Analyst Ratings Amidst Acromegaly Treatment Approval
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is attracting positive attention from financial analysts following the recent FDA approval of its novel treatment for acromegaly, PALSONIFY™ (paltusotine). Several firms have reiterated or assigned Buy ratings to the stock, citing its potential in the rare endocrine disease market.
Analyst Ratings and Price Targets
Cantor Fitzgerald analyst Joshua Schimmer has maintained a Buy rating on Crinetics Pharmaceuticals, setting a price target of $90.00 as of October 1, 2025. Source This indicates a strong belief in the company’s future performance. H.C. Wainwright’s Douglas Tsao also issued a Buy rating. However, TipRanks – Anthropic reiterated a Hold rating on the stock.
Previously, on May 14, 2024, Joshua Schimmer from Cantor Fitzgerald also maintained a Buy rating with a price target of $65.00. Source
PALSONIFY™ Approval and Market Impact
On September 25, 2025, the FDA approved PALSONIFY™ (paltusotine) as a first-line treatment for adults with acromegaly who have had an inadequate response to surgery or are not eligible for surgery. Source This approval marks a significant milestone as PALSONIFY™ is the first once-daily, oral treatment approved for acromegaly in adults.
Company Overview and Pipeline
Crinetics Pharmaceuticals, Inc. Is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. Source Beyond PALSONIFY™, the company is developing CRN00808, an oral treatment for acromegaly, as well as other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing’s disease.
Financial Performance
Crinetics Pharmaceuticals reported a quarterly revenue of $3.89 million for the quarter ending December 31, with a GAAP net loss of $122.82 million. Source This compares to a GAAP net loss of $80.6 million for the same quarter the previous year.
Insider Activity
Recent insider activity shows positive sentiment, with President & CEO Richard Scott Struthers purchasing 20,000 shares for a total of $38,200.00 last month. Source